Inogen Inc. Files 8-K on Financials
Ticker: INGN · Form: 8-K · Filed: May 7, 2024 · CIK: 1294133
| Field | Detail |
|---|---|
| Company | Inogen Inc (INGN) |
| Form Type | 8-K |
| Filed Date | May 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: INGN
TL;DR
Inogen filed its 8-K. Financials are in. Check it out.
AI Summary
On May 7, 2024, Inogen Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and exhibits, but does not specify any new material events or significant financial figures within the provided text.
Why It Matters
This filing provides an update on Inogen Inc.'s financial condition and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Inogen Inc. (company) — Registrant
- May 07, 2024 (date) — Date of earliest event reported
- 859 Ward Drive, Goleta, California 93111 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Inogen Inc.?
The primary purpose of this 8-K filing is to report on Inogen Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is May 07, 2024.
What is Inogen Inc.'s principal executive office address?
Inogen Inc.'s principal executive office is located at 859 Ward Drive, Goleta, California 93111.
What is the Commission File Number for Inogen Inc.?
The Commission File Number for Inogen Inc. is 001-36309.
What is the SIC code for Inogen Inc.?
The Standard Industrial Classification (SIC) code for Inogen Inc. is 3842, which corresponds to Orthopedic, Prosthetic & Surgical Appliances & Supplies.
Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-05-07 16:10:15
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value INGN The Nasdaq Stock Mar
Filing Documents
- ingn-20240507.htm (8-K) — 39KB
- ingn-ex99_1.htm (EX-99.1) — 442KB
- img132417817_0.jpg (GRAPHIC) — 3KB
- 0000950170-24-054483.txt ( ) — 612KB
- ingn-20240507.xsd (EX-101.SCH) — 23KB
- ingn-20240507_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On May 7, 2024, Inogen, Inc. (the "Company") issued a press release reporting its financial results for the first quarter ended March 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release dated May 7, 2024. 104 The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. INOGEN, INC. Date: May 7, 2024 By: /s/ Michael Bourque Michael Bourque Executive Vice President Chief Financial Officer Treasurer (Principal Accounting and Financial Officer)